


May 10 – 12, 2010

3rd European Conference for Clinical Nanomedicine (With Foyer-Exhibition and University Presentation Village)

Call for Posters & Papers and Updated Preliminary Programme

CLINAM



European Foundation for Clinical Nanomedicine

Welcome to the 3rd European Conference for Clinical Nanomedicine. We look forward to meet the Nanomedicine Community in Basel We have already many Paper-and Poster- submissions and look forward to many more! Find enclosed the “Exhibition” Registration and the “University Village” Registration.

Call for Papers - Regulations

Papers submitted must cover original research aimed at future or current **clinical application** of Nanoscience. This includes clinical trial designs, reports of ongoing and completed clinical trials, preclinical work, and technology papers with a clinical long-term vision. Submitted papers will undergo peer grading; **accepted papers are chosen for oral or poster presentation**. Oral sessions will include:

- **Sessions on the following clinical topics:** Nanomedicine for cardiovascular disease, oncology, haematology, neurology / neurosurgery, implants, inflammation, orphan diseases, dermatology, eye disease, ear disease, tissue repair, orthopaedics and many others.
- **Technology sessions, including nano-systems,** nanoparticles, nanoanalytics and diagnostics, toxicology, nano-imaging, targeted drug delivery using nanoparticles, GMP and quality assurance, and others...
- **Sessions focusing on the implications** of Nanomedicine for society, developing countries, the environment, public health finance and other subjects.
- **Sessions describing** in detail unsolved medical problems for which a novel solution is proposed.
- **Sessions proposing novel hypotheses,** concepts and ideas, if they can be supported by thorough reasoning.

Procedure

The submission must be written in Microsoft Word, RTF, or Open document file format, using Arial Narrow 11 point font size with single spacing and must fit on two pages, including metadata and figures. All illustrations, figures, and tables are placed within the text at the appropriate points. Make sure that margins left and right are at least 2 cm.

Please mail your document to submission@clinam.org by noon on March 1, 2010, at the latest

A receipt message will be sent to you..

Precedent meetings to the Conference

Sunday, May 9, 2010

14.00	Registration (14.00 – 16.00 and 18.00 – 19.30)
15.00	General Assembly of the European Society for Nanomedicine (Business-meeting)
17.00	Meeting of the International Society for Nanomedicine (Business-meeting)
19.45	Welcome Dinner with the Speakers of the Conference

Since the sessions start Monday Morning at 08.45 it is advisably to travel to Basel already on Sunday evening.

Updated Preliminary Programme (Status February 16, 2010)

Monday, May 10, 2010

07.30 Registration (from 07.30 until 18.00)

Plenum Session

08.45 1. Opening of the Conference

Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine, Basel (CH)
Federal Councillor Didier Burkhalter, Federal Department of Home Affairs, Bern (CH)
Dr. Roland Schenkel, European Commission, Brussels, Director General of the Joint Research Centre (JET) (B)
Dr. Carlo Conti, Chancellor of the Governing Council of the Canton Basel-Stadt, Vice-President of the board of the Swiss Conference of the Cantonal Ministers of Public Health, Basel (CH)

09.45 2. Roadmap to Translate the Knowledge to Practice

The Roadmap of Nanomedicine Towards the Patient

Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, University Hospital, Basel (CH)

10.10 Keynote lecture

The Complexity of HIV Interaction with its Hosts as Revealed at the Nanometric Level

Prof. Dr. med. Luc Montagnier, President and CEO of Nanectis Biotechnology SA, and President of the World Foundation Aids Research and Prevention, UNESCO, Nobel Laureate, Paris (F)

10.50 Questions

11.00 Break

11.30 3. Unsolved Problems Waiting for Nanomedical Solutions 1

Unsolved Problems in Modern Management of Coronary Artery Disease

Prof. Dr. med. Frans van de Werf Director of the Leuven Clinical Coordinating Centre and Chair of the Department of Cardiovascular Medicine, Leuven (B)

Unsolved Problems in Diabetes

Prof. Dr. med. John Pickup MA, BM, BCh, DPhil, FRCPath, Professor of Diabetes and Metabolism Kings College, London (UK)

Unsolved Problems In Bacterial Infections

Prof. Dr. med. Winfried V. Kern, Head, Division of Infectious Diseases, Department of Medicine, Albert-Ludwigs-University, Center for Infectious Diseases & Travel Medicine, and Center for Chronic Immunodeficiency, University Hospital Freiburg and member of the Executive Committee of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Freiburg (D)

Unsolved Problems in Lung Disease

Prof. Dr. med. Nikolaos M. Siafakas, PhD, FRCP, Department of Thoracic Medicine, University General Hospital, Heraklion, and President of European Respiratory Society, Thoracic Medicine, Crete, (GR)

Unsolved Problems in Dermatology

Prof. Dr. med. Lars E. French, Chairman, Department of Dermatology, Zurich University Hospital, Zürich (CH)

12.30 Questions & Discussion

13.00 Lunch

14.30

4. Nanoscience Technologies for Solving Medical Problems 1

New (bio) Materials for Nanodevice Construction

Prof. Dr. Patrick Couvreur, Director UMR CNRS 8612, Physico-chimie Pharmacotechnie et Biopharmacie, University of Paris-Sud, Chatenay-Malabry (F)

Using Self-Assembled Nanomaterials to Inhibit the Formation of Metastatic Cancer Stem Cell Colonies in Vitro

Prof. Dr. Rutledge Ellis-Behnke, Massachusetts Institute of Technology, Cambridge (USA) and University of Hong Kong (China)

Superparamagnetic Nanoparticles: the Universal Tool for Diagnosis and Therapy!?

Prof. Dr. Heinrich Hofmann, EPFL, Laboratoire de Technologie des Poudres, Lausanne (CH)

Supramolecular Structures as Nanocarriers in Gene and Drug Delivery -Challenge to Smart Molecular Therapy

Prof. Dr. Kazunori Kataoka, Department of Materials Engineering Graduate School of Engineering and Division of Clinical Biotechnology Center for Disease Biology and Integrative Medicine Graduate School of Medicine, The University of Tokyo (Japan)

Drug Delivery Across Biological Barriers: Intestines, Skin and Lung.

Prof. Dr. Claus-Michael Lehr, Chair for Biopharmaceutics and Pharmaceutical Technology Saarland University, Saarbrücken (D)

Biofunctional Nanoparticles for Targeted Medical Imaging

Prof. Dr. Marcus Textor, ETH Zurich, BioInterfaceGroup, Laboratory for Surface Science and Technology, Department of Materials, Zurich, (CH)

Immunotoxicity and Immunogenicity of Nanodrugs – Two Sides of a Coin?

Prof. Dr. med. Dr. Sc. Janos Szebeni, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H)

16.00

Questions & Discussion

16.35

Break

17.15

5. Late Breaking and Ongoing Clinical Trials in Nanomedicine 1

Progress toward Phase I Human Trials Using a PAMAM Dendrimer Based MRI Contrast Agent for Lymphatic Imaging

Prof. Dr. Donald Tomalia, Director of the National Dendrimer & Nanotechnology Center, Central Michigan University, Mt. Pleasant, (USA)

Nano-Packaging of siRNA: Rationale and First Clinical Experience

Prof. Dr. Pieter Cullis, Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, (Canada)

Immunostimulatory Nano-particles for the Causal Treatment of Allergic Rhinitis: Results from a Phase IIb Study in 300 Patients Suffering from House Dust Allergy

Dr. Wolfgang A. Renner, CEO, Cytos Biotechnology Ltd, Schlieren (CH)

Clinical investigation of DermaVir Nanomedicine in HIV-Infected Patients

Prof. Dr. Julianna Lisziewicz, CEO of Genetic Immunity, Budapest, (H)

Should the Peripheral Endocannabinoid System be Targeted for the Treatment of the Metabolic Syndrome? (Towards Clinical Trial)

Prof. Dr. med. George Kunos, PhD, Scientific Director of the National Institute on Alcohol Abuse and Alcoholism, National Institute of Health, Bethesda, MD, (USA)

18.15

Questions & Discussion

- 19.00 *Special Presentation of the ETP Nanomedicine*
The European Technology Platform Nanomedicine – the complement to CLINAM
 Bertrand Loubaton, MBA, Chairman ETP Nanomedicine, Director, Pharmaceutical & Academic
 Research Collaboration, Academic Programs, GE Healthcare Europe, Paris / Brussels
- 19.10 *End of Conference Day 1*
- 19.45 *Official CLINAM Evening Event:*
 Walking to St. Elisabeth Church: Dinner with Surprise: “Nano Steel Particles and Basic Carriers”,

Tuesday, May 11, 2010

08.00 6. Emphasis Session on Cancer - Nanomedical Approaches

Two Parallel Sessions A and B

Session A Cancer Nanomedicine

08.00 1. Nanoparticles Interacting with Cells

Cellular Binding & Uptake of Nano-Objects

Dr. med Volker Mailänder, Leader of the joint research Group between the University Clinic of Medicine III, Mainz and the Max Planck Institute for Polymer Science, Mainz (D)

Enzymatic Degradation of Nanoobjects

Prof. Dr. Valerian E. Kagan, PhD, DSc, Vice Chairman of the Department for Environmental and Occupational health (EOH), University of Pittsburg, (USA)

Intracellular Handling, Trafficking and Breakdown of Nanoobjects

PD Dr. Maija Vihinen-Ranta, Academy Research Fellow, NanoScience Center, Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä (FIN)

Biologic Pathways as Target of Nanodrugs – Targeting Cancer-Stem Cells Without Harming Normal Stem Cells

Prof. Dr. Jan Mollenhauer, University of Southern Denmark Head Molecular Oncology Director of Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN, Odense, (DK)

08.50 *Questions & Discussion*

09.20 2. Nanoparticles Interacting with the Organism

Cancer Vascularisation and Lymphatics – the Fundamental Access Routes for Targeted Therapies

Prof. Gerhard Christofori, PhD, Head of the Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel (CH)

Uptake and Elimination Pathways of Nanoparticles

Dr. Khuloud Al-Jamal, Senior Research Fellow, Nanomedicine Lab, University of London, (UK)

Targeted Nanomedicines: Importance of Size, Ligands and EPR

Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Dept. of Pharmaceutics, Utrecht University (NL)

09.55 *Questions & Discussion*

10.20 *Break*

- 10.50 **3. Nanoparticles Interacting with Disease**
- Drug Targeting – Quantitative and Qualitative Advantages of Nanodrugs to Conventional Therapy and Monoclonal Antibodies - a Review of Preclinical Evidence*
Speaker to be announced
- Advanced Functionality (siRNA, Photodynamic Therapy, Artificial Organelles)*
Prof. Dr. med. Patrick Hunziker, Dep. Chief of the Intensive Care Clinic of the University of Basel, President of the European Society for Nanomedicine, Basel (CH)
- Overview on Molecular ligand- and target-systems in cancer*
Speaker to be announced

11.30 *Questions & Discussion*

12.00 *End of Session*

(Continuation: Session 8 in Plenary Hall at 12.20)

Session B **Nanomaterial approaches for Cancer Diagnosis, Imaging and Nanotoxicology**

08.00 **1. In Vitro Diagnosis: Nanotech Biomarker Detection**

Cancer Biomarkers – the Prospect of Nano-arrays for Cancer Proteomics
Prof. Dr. med. Simo Schwartz, Jr., PhD Nanomedicine Coordinator Molecular Biology and Biochemistry Research Center for Nanomedicine (CIBBIM-Nanomedicine) Vall d'Hebron University Hospital Research Institute, Barcelona (SP)

Lab-on-chip for Nucleic Acid and Protein Cancer Biomarkers
Prof. Dr. med. François Berger, Université Joseph Fourier, directeur de l'unité Nanomédecine et cerveau de l'INSERM, Grenoble (F)

Detection of Circulating Cancer Cells
Prof. Dr. Silke Krol Istituto Neurologico Carlo Besta, Milano - Fondazione IRCCS, Milano (I)

08.40 *Questions & Discussion*

09.05 **2. Nanotech Imaging & Monitoring**

Nanomaterial MR imaging for Cancer and Other Disease – Clinical / Preclinical
Prof. Dr. Klaas Nicolay, Dept. of Biomedical Engineering, Technical University, Eindhoven (NL)

Nanomaterial fluorescence imaging – clinical and preclinical
Patrick Boisseau, Coordinator of Nano2Life, PM, CEA-Leti, Grenoble (F)

Nanoparticles for Nuclear Medicine: Advantages in PET, SPECT, Radiotherapy
Speaker to be announced

09.40 *Questions & Discussion*

10.20 *Break*

10.50 **3. Nanotoxicology**

Abolishing Systemic Toxicity by Nano-formulation of Drugs
Prof. Dr. Paul Borm Director of Centre of Expertise in Life Sciences, Hogeschool Zuyd, Heerlen and CEO/CSO, of Magnamedics Diagnostics BV, Geleen (NL)

Expected and Unexpected Side Effects of Nanodrugs
Dr. Laurent Lévy, CEO, Nanobiotix, and Co-President of the French Technology Platform on Nanomedicine (FTPN), Paris (F)

Toxicokinetic Profile of Hard and Soft Nanoparticles
Prof. Dr. Kostas Kostarelos, School of Pharmacy, University of London (UK)

11.35 *Questions & Discussion*

12.00 *End of Session*

Plenum Session

12.10 **7. Therapy of Unsolved Problems in Cancer**

Keynote Lecture

The Therapy of Solid Tumors

Prof. Dr. med Kathy Pritchard-Jones, President of the European Society for Pediatric Oncology, Institute of Cancer Research, Sutton (UK)

12.30 *Questions & Discussion*

13.00 *Lunch*

14.15 **8. Cancer Drugs – Clinical Trials in Nanomedicine**

Clinical Application of Nano-liposomal drugs for Cancer: Proven Advantages and Open Questions

Prof. Dr. med. Alberto Gabizon, Hebrew University, Jerusalem, (IL)

Thermotherapy with Magnetic Nanoparticles: Survival Benefit for Glioblastoma multiforme Patients

Dr. rer. nat. Andreas Jordan, CSO, magForce Nanotechnologie AG, Berlin (D)

Tumor-targeting Nanodelivery Platform – New Trials and Results

Prof. Dr. Esther Chang, Georgetown University Medical Center, Department of Oncology and Otolaryngology Lombardi Comprehensive Cancer Center, Washington (USA)

14.50 *Questions & Discussion*

Panel 1 Selected Nanoparticles in Cancer

15.15 *Selected Nanoparticles in Cancer - What has been proven clinically and what is the clinical evidence from established nanodrugs?*

Participants to be announced

16.15 *Break*

Keynote Lecture

Multifunctional Pharmaceutical Nanocarriers: What we can expect

Prof. Dr. Vladimir P. Torchilin, Ph.D, D.Sc, Distinguished Professor, Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University Boston, MA (USA)

17.15 *Questions & Discussion*

17.30 **9. Late Breaking Trials 2 / Nanoscience Technologies in Nanomedicine 2 and 3**

Three Parallel Sessions A, B and C

Session A Late Breaking and Ongoing Clinical Trials in Nanomedicine 2

17.30 *Five open papers*

18.30 *Questions & Discussion*

19.00 *End of Conference Day 2*

Session B **Nanoscience Technologies for Solving Medical Problems 2**

17.30 *Visual single Cell Proteomics with Microfluidics: Vision and Preliminary Results*
Dr. Thomas Braun, Senior Scientist, University of Basel, (CH)

Chemotherapy with Magnetic Nanoparticles – an Innovative Method for Local Cancer Treatment
Prof. Dr. med. Christoph Alexiou, Head Division for Experimental Oncology and Nanomedicine at the Dept of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital Erlangen, (D)

The Nanostructure of Human Teeth: Biologically Inspired Dental Treatments
Prof. Dr. Bert Müller, Biomaterials Science Center, Basel (CH)

Two open papers

18.30 *Questions & Discussion*

19.00 *End of Conference Day 2*

Session C **Nanoscience Technologies for Solving Medical Problems 3**

17.30 *Five open papers*

18.30 *Questions & Discussion*

19.00 *End of Conference Day 2*

19.15 *Aperitif*

20.15 *Speakers Dinner & Guests of the Foundation*

Wednesday, May 12, 2010

Plenum Session

08.00 10. Unsolved Problems Waiting for Nanomedical Solutions 2

Unsolved Problems in Malaria

Prof. Dr. Bob Sinden, Prof. of Cell Parasite Biology, Head of Infection and Immunity Section and Department of Biological Sciences, Imperial College of Science, Technology and Medicine, London (UK)

Unsolved Problems in Hereditary Cancer

PD Dr. med. Karl Heinimann, PhD Genetics Department, Children Hospital Basel, (CH)

Unsolved Problems in Inflammation in Intensive Care Medicine

Prof. Dr. med. Didier Payen de la Garanderie, Hospital Lariboisière, Paris (F)

Blood Brain Barrier / Neurology

The Unsolved Problem of Targeted Therapy to the Brain – How to Measure efficiency

Prof. Dr. Margareta Hammarlund-Udenaes, Ph.D., Professor of Pharmacokinetics and Pharmacodynamics, Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences, Uppsala University (S)

08.50 *Questions & Discussion*

09.20 *Break*

Two Parallel Sessions A and B

09.50 **11. Nanoscience Technologies for Solving Medical Problems 4 / Ethics / Regulations and University Presentations**

Session A **Nanoscience Technologies / Ethics**

09.50 **1. Nanoscience Technologies for Solving Medical Problems**

The Portfolio of Presently Nanomedical Targeted Diseases – Principles and practice
Speaker to be announced

New Insights on Multifunctional Nano-platform Against Cutaneous Leishmaniasis

Prof. Dr. Eder Leila Romero, Director of the Nanomedicine Research Program (NRP), Universidad Nacional de Quilmes, Buenos Aires (Argentina)

Triple presentation on SPIONS

a) Nano-Immunology: SPIONS Modulate Dendritic Cell Function and T Cell Responses

Dr. med. Christoph von Gantner, Respiratory Physician, Bern University Hospital, Bern (CH)

b) Multifunctional Use of Paramagnetic Iron Oxide Nanoparticles in Drug and Cell Delivery.

Prof. Dr. Paul Borm Director of Centre of Expertise in Life Sciences, Hogeschool Zuyd, Heerlen and CEO/CSO, of Magnamedics Diagnostics BV, Geleen (NL)

c) Nanoparticles In Medicine – Regulated Entry and Orchestrated Trafficking, Where is the Risk?"

Prof. Dr. med. Peter Gehr, Chairman of the Institute of Anatomy, University Bern, (CH)

10.35 *Questions & Discussion*

11.00 **2. Ethics**

The Ethical Component of Regulating Nanomedicine

Dr. Richard Moore, Head of Nanomedicine and Lifesciences at the Institute of Nanotechnology, Stirling (UK)

Promises.. Progress.. Predicament - What will Nanomedicine Really Bring to Human Society?

Dr. Donald Bruce, Edinethics Ltd., Edinburgh, Scotland (UK)

11.30 *Questions & Discussion*

(Continuation: Session 12 in Plenary Hall at 12.00)

Session B **Regulations-Session / University Small Talks**

09.50 **1. Regulations and Industry Related Matters**

Translation Research from Bench to Clinic and its Cross-Reference with Regulatory Hinderance

Prof. Dr. Rogério Gaspar, Nanomedicine & DDS group, iMed.Ul and Faculty of Pharmacy, University of Lisbon (P)

What does Healthcare Translatability Mean for Nanomedicine– and Whose View Counts?

Prof. Dr. Mike Eaton, Head of Biological Chemistry, UCB, Slough (UK)

Drug Loaded Immunonanoparticles in the Combat of Cancer Stem Cells - Safety and Efficacy Considerations"

Prof. Dr. Jürgen Borlak, Chair Pharmaco- and Toxicogenomics, Medical School Hannover, Director, Fraunhofer Institute of Toxicology and Experimental Medicine, (Fh-ITEM), Head of Department 'Molecular Medicine and Medical Biotechnology, Hannover, (D)

Predicting Toxicity and Environmental Relevance of Nanoparticles – a Regulatory Approach.
Prof. Dr. Wendelin Stark, Institute for Chemical and Bioengineering, ETH Zurich (CH)

10.30 *Questions & Discussion*

10.50 **2. University “Small Talks”**

Twelve 5-minute Presentations of Selected Universities and Institutes
Announced in Final Programme

Plenum Session

12.00 **12. Nanoscience Technologies for Solving Medical Problems 5**

Mechanotransduction: Mechanisms of Mechano-Chemical Signal Conversion
Prof. Dr. Viola Vogel, Department of Materials Laboratory for Biologically Oriented Materials ETH Zürich (CH)

Emerging Micromechanical and Nanofluidic Technologies for Medical Diagnostics
Prof. Dr. Giacinto Scoles, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I) and Biology Department, Temple University, Philadelphia, PA (USA)

Novel Facts for Carbon Nanotubes in Brain Disease Including First Data
Prof. Dr. Kostas Kostarelos, School of Pharmacy, University of London (UK)

12.45 *Questions & Discussion*

13.15 *Lunch*

Panel 2 Saving Lives vs. Avoiding Risks – In Developed and in Developing Countries

14.30 The fundamental motivation of medicine is to benefit the patient without adding harm. How can benefit be defined or measured for individuals, and what is risk in science for society? How can a benefit for an individual or a group of patients be weighted in relation to potential or unknown risks? Is it ethical to treat a human individual with a lethal disease with a novel therapeutic approach of uncertain efficacy or unproven safety or is it more ethical to withhold the therapy? Is the current practice of drug development suited to individual severe disease, to orphan disease, in children, in the elderly, in the developing countries? Facing the nanomedicine paradigm of composite therapeutic systems that can be tailored to an individual patient, what new avenues in drug development and regulation need to be taken?

Participants:

Prof. Dr. Werner Arber Nobel Laureate, Basel

Dr. Donald Bruce, Edinethics, Scotland

Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, Basel

Prof. Dr. med. George Kunos, PhD, Scientific Director, National Institute of Health, Bethesda, MD, USA

Prof. Dr. Jean Marie Lehn, ISIS, Université Louis Pasteur, Strasbourg and Collège de France, Paris, Nobel Laureate, Strasbourg (t.b.c)

Prof. Dr. med Matthias Pfisterer, University Hospital Basel

Prof. Dr. Heinrich Rohrer, IBM Fellow, Retired Nobel Laureate, Wollerau

Dr. Beat Schmid, Head of Preclinical Review, Swissmedic, Bern

Dr. Andreas Wallnöfer, Global Head Clinical Research and Exploratory Development, F.Hoffmann-La Roche, AG Basel (CH)

Dr. Thomas Lönnngren, Executive Director, European Medicines Agency, (former emea), London (UK)

16.00 *Closing remarks*

Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, Basel (CH)

16.15 *End of conference*

Scientific Committee of the Conference

Chairpersons:

- Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, Basel, (CH) (*Medical Chair*),
- Prof. Dr. Gert Storm, Member of the Board of Trustees of the CLINAM-Foundation, Utrecht, (NL) (*Scientific Chair*),

Members:

- Prof. Dr. Joachim Seelig, Biozentrum, University, Basel, (CH)
- Prof. Dr. med. Matthias Pfisterer, University Hospital Basel, (CH),
- Prof. Dr. Giacinto Scoles, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I)
- Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine, Basel, (CH)
- Prof. Dr. Marcus Textor, Head of Laboratory for Surface Science and Technology, ETH Zurich (CH)
- Patrick Boisseau Member of the Board of the European Technology Platform for Nanomedicine (ETPN), Grenoble (F)
- Dr. med. Dieter Scholer, member of the *Swiss Academy* of Medical Sciences, Basel (CH)
- Prof. Dr. med Janos Szebeni, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H)

General Information

Event Scheduling

Conference: From Sunday, May 9, 5 pm until Wednesday May 12, 4 pm

Exhibition: From Monday, May 10, 10 am until Wednesday, May 12, 2010, 2 pm

University Village: From Monday, May 10, 2010, 10 am until Wednesday, May 12, 3 pm

Organisers

The European CLINAM Foundation for Clinical Nanomedicine, Basel, Switzerland (www.clinam.org)

in cooperation with the European Society for Nanomedicine (www.esnam.org)

Responsible: Beat Löffler, MA, CEO and Prof. Patrick Hunziker, MD, CSO of the European Foundation for Clinical Nanomedicine, Basel, Switzerland.

Office

European Foundation for Clinical Nanomedicine Alemannengasse 12, P.O. Box, CH-4016 Basel, Switzerland

Phone: + 41 61 695 93 95 Fax: + 41 61 695 93 90 Mail: clinam@clinam.org

Target Audience

The faculty of this conference includes pioneers, opinion leaders and active researchers from medicine and nanoscience, who share their experience and interact in a highly inter-disciplinary manner that widens the mutual understanding for both sides. The conference and exhibition are aimed at clinical physicians as well as nanoscientists with a background of pharmacology, biology, physics, chemistry, biophysics, materials science and engineering, all involved in the development or clinical application of nanomedicine. The event is also of interest for policy makers, experts from industry in the field of life sciences and those involved in the development of new tools and materials for nanomedicine, as well as all those investigating the potential of future emerging technologies. Experts from venture companies can also acquire knowledge here on both, existing and upcoming developments and novel products in the emerging field of nanomedicine.

Board of Trustees of the European Foundation for Clinical Nanomedicine

- Dr. iur. Alexander Gutmans • Prof. Dr. med. Patrick Hunziker • Beat Löffler, MA • Prof. Dr. Hans Joachim Güntherodt
- Susy Hunziker, lic. phil. • Prof. Dr. med. Matthias Pfisterer • Prof. Dr. med. Stephan Marsch • Prof. Dr. Gert Storm

European Society for Nanomedicine - Executive Council

- Prof. Dr. med. Patrick Hunziker • Beat Löffler, MA • Prof. Dr. med. Jacques-André Bazex • Dr. Frank Sinner • Prof. Dr. med. Hans Myhre • Prof. Dr. Gert Storm • Prof. Dr. med. Dr. h.c. Fritz Bühler • Prof. Dr. Jacques Chambon • Prof. Dr. Joachim Seelig

The Members of the Advisory Board of the CLINAM-Foundation

- Prof. Dr. Dr. h.c. Zhores Alferov, Physicist, Nobel Laureate, Moscow • Prof. Dr. Werner Arber, Biologist and Biophysicist, Nobel Laureate, Basel • Prof. Dr. med. Jacques André Bazex, Member of the French National Academy of Medicine, Toulouse • Patrick Boisseau, CEA-Leti-Minatec, Grenoble and Member of the Board of the European Technology Platform for Nanomedicine (ETPN), Brussels / Grenoble • Prof. Dr. Dr. h.c. Fritz Bühler, Director of the European Centre for Pharmaceutical Medicine (ECPM), Basel • Dr. med. Victor Brantl, M.Sc., Vice-President, R&D, Mepha Ltd, Aesch, • Dr. Andreas Burckhardt, Director of the Basel Chamber of Commerce, Basel • Dr. Peter Burckhardt, CEO, EVA, The Basel Life Sciences Start-up Agency, Basel • Dr. Beat Butz, Coordinator of the Swiss National Foundation, Bern • Prof. Dr. med. Jacques Chambon, French Academy of Sciences, Strasbourg/Paris • Prof. Dr. med. Patrick Couvreur, Director of the Centre d'études Pharmaceutiques (CNRS), Paris • Dr. Christoph Eymann, Member of the Governing Council of the Canton of Basel, Basel • Prof. Dr. Theodor W. Guentert, F. Hoffmann-La Roche Ltd., Non-clinical Safety,

Basel • Prof. Dr. Gerda Huber, Director of School of Life Sciences, Muttenz, Switzerland • Prof. Dr. Kazunori Kataoka, Head of Graduate School of Engineering and Division of Clinical Biotechnology, Graduate School of Medicine, The University of Tokyo (Japan) • Prof. Dr. Silke Krol, Istituto Neurologico Carlo Besta Milano - Fondazione IRCCS. Milano • Prof. Dr. Kostas Kostarellos, Chair holder Nanomedicine, University of London • Prof. Dr. Karl J. Lackner, President, German Association for Clinical Chemistry and Laboratory Medicine, Mainz • Prof. Dr. Jean Marie Lehn, ISIS, Université Louis Pasteur, Strasbourg and Collège de France, Paris, Nobel Laureate • Prof. Dr. med. Klaus Lindpaintner, MPH, FACP Vice President, R&D, and Chief Scientific Officer, Strategic Diagnostics Inc., Newark, • Prof. Dr. Stergios Logothetidis, Aristotele University of Thessaloniki, • Prof. Dr. med. Peter Meier-Abt, Vice-principal and Head of Research, University of Basel • Prof. Dr. Hans Myhre, Surgeon at the University Hospital, Oslo • Dr. Romeo Paioni, Head of Scientific and External Affairs, Novartis, Basel • Prof. Dr. Heinrich Rohrer, Physicist, Nobel Laureate, Wollerau • Dr. med. Dieter Scholer, member of the Swiss Academy of Medical Sciences, Basel • Prof. Dr. Christian Schönenberger, Director of the Swiss Nanoscience Institute, Basel • Prof. Dr. med. Jürg Schifferli, Head Internal Medicine, University Hospital and board member of the Swiss National Foundation, Basel • Prof. Dr. Giacinto Scoles, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I) • Prof. Dr. Joachim Seelig, Biozentrum, Basel • Prof. Dr. Paul Siffert, Secretary General, European Research & Materials Society, (EMRS) Strasbourg • Dr. Frank Sinner, Director of the BioNanoNet-Research Society, Graz • Prof. Dr. med. Dr. Sc. Janos Szebeni, Head of Department of nanomedicine, Bay Zoltán Institute of Nanotechnology, Budapest (H) • Prof. Dr. Donald Tomalia, Director of the National Dendrimer & Nanotechnology Center, Central Michigan University • Dr. med. Panagiotis Trohopoulos, Cardiologist and Nano-Physician, Thessalonica.

Conference Fees

	Fee until Jan. 31, 2010	Fee as from Feb. 1, 2010	Fee after April 23, 2010	One day	One day after April 23	
Academy esnam member	540.-- €	580.-- €	620.-- €	230.-- €	270.-- €	When receiving your registration the organiser will send to you an invoice
Academy regular	665.-- €	725.-- €	765.-- €	320.-- €	360.-- €	
Industry esnam member	795.-- €	895.-- €	935.-- €	520.-- €	560.-- €	
Industry regular	895.-- €	995.-- €	1035.-- €	595.-- €	635.-- €	
Student esnam member	335.-- €	385.-- €	425.-- €	150.-- €	190.-- €	
Student regular	435.-- €	485.-- €	500.-- €	210.-- €	250.-- €	
Evening Event on May 10: your contribution to the expenses 50.-- € (please mark)						
Please note: A surcharge 25% will be added for registration on site						

Accommodation

The official conference hotel is the Swissôtel Le Plaza***** in 200 m distance from the conference hall. All participants have a special room rate of CHF 285. – (about 175.– Euro), if indicating their participation in the Nanomedicine-Conference. Booking through: Swissôtel Le Plaza, Messeplatz 25, CH-4005 Basel, phone +41 61 555 3333 E-Mail: <https://reservations.swissotel.com/Availability.aspx?property=SBA&promo=GCLI&lang=en> Other hotels can be provided through Basel Tourism: 4-star hotels CHF 180.00 - 220.00, 3-star hotels: CHF 150.00-180.00, 2-star hotels: CHF 130.00 - 150.00 Booking through: Basel Tourism Tel. +41 61 268 68 58 online on www.basel.com under "accommodation".

The CLINAM Foyer Exhibition 2010 (May 10-12, 2010)

Pioneers in Nanomedicine related tools and Technology

The pioneers in nanomedical applications have the opportunity to show alongside the Conference, what is already available in the market. The exhibitors can expect 250-300 people that belong to the Nanomedicine community. Half of the participants are clinicians. Everyone who already has products, processes or treatment applications is keen to show them to the experts and decision makers who will decide what to use in the future.

The best Target Group to introduce your exhibits

The best target groups for such exhibitions are clinicians, the interdisciplinary group of experts in biology, chemistry and physics and the decision makers from research institutes and the pharmaceutical industry. The attached registration form contains details and costs-Information.

The CLINAM University Village 2010

The New Role of the Universities for Translation of Research

The turbulent economy and worldwide competition make it necessary that the innovation process in this fast-moving field becomes faster and more efficient. In this context, the leadership role of the universities to shape the future by innovation, both in fundamental and applied research is a challenge, especially in a field where technologies strongly interact with life sciences and clinical medicine. To bring academic research in the nanosciences to practical fruition in clinical medicine, partnering as well as competition with other universities is an important mosaic stone to success.

Ideas, Inventions and Projects

The CLINAM Nanomedicine University Village 2010 from May 10-12 will give ample opportunity for presenting novel approaches, new research projects and initial outcomes of research and experimental results. Universities and Institutes show the latest development of inventions in Nanomedicine. They show posters or exhibits of recently developed activity and eventually already patented nanomedical inventions

Posters and “Small Talks”

Posters, results and presented objects within the University Village are subject to short presentations in a special session “Small Talks” are max. 5 minutes in length and will serve to highlight the research activities displayed on the poster. A poster is conditional to be invited for a “Small Talk” The rules are as follows: Each selected Small Talk should comprise a maximum of three slides, with very simple graphics (no videos):

- **Slide 1:** general introduction to the topic of your field, presented in a way that is accessible to the highly interdisciplinary audience,
- **Slide 2:** shows some of the highlights of your work, encouraging people to come and talk to you for more details, since there will not be enough time to go through all your work and scientific data,
- **Slide 3:** shows how the work fits into the area of Nanomedicine and where you see it going in the future.

Topics are all topics of the conference and all disciplines of Nanotechnology that meet Nanomedicine applications and needs.

Low Cost

CLINAM has kept the costs for participation in this event as low as possible. The fee for a Village Table, a Socket and Poster Pin-Boards, including one transferable conference badge, including lunch is € 580 Euro Presenters of Small Talks will be given the opportunity to present their university within the Summer Edition of the European Journal for Nanomedicine

Background of the Organising Bodies

The European Foundation for Clinical Nanomedicine (CLINAM-Foundation)

The European Foundation for Clinical Nanomedicine is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of nanoscience in medicine. Aiming at prevention, diagnosis, and therapy through Nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of nanoscience on medicine and the observed rapid advance of medical applications of nanoscience have been the main reasons for the creation of the Foundation. www.clinam.org

The European Society for Nanomedicine (esnam)

The European Society for Nanomedicine was founded in April 2007 The Society is a registered, non-profit, non-governmental organisation with seat in Basel, Switzerland. It is the platform for all experts involved in clinical Nanomedicine. It is the forum for debating on a multidisciplinary clinical level and to establish professional contacts between clinicians, researchers at the universities and in the industry as well as developing alliances with the engineers and technicians who develop tools for clinical Nanomedicine. The Society is the bridge for all in clinical Nanomedicine involved experts to create together an interdisciplinary clinical forum and furthering the translation from research and development to products for the benefit of the patient. www.esnam.org

CONFERENCE REGISTRATION FORM

I register for the **Third European Conference for Clinical Nanomedicine**.

	Regular	Member	Early Registration
Academy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Industry	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Students	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Exhibitor ticket (**Transferable**) 780. -- €; (only **one** transferable ticket per exhibitor)

I participate in the **evening event** on May 10, 2010 at the support rate of 50. -- €

Title: _____

Last name: _____ First name: _____

Profession: _____ Company / University: _____

Department / Affiliation _____ Address: _____

ZIP code: _____ Town: _____

Country: _____ Phone: _____

Fax: _____

E-Mail: _____

Legally binding Signature: _____ Date: _____

	Fee until Jan. 31, 2010	Fee as from Feb. 1, 2010	Fee after April 23, 2010	One day	One day after April 23	
Academy esnam member	540. -- €	580. -- €	620. -- €	230. -- €	270.-- €	When receiving your registration the organiser will send to you an invoice
Academy regular	665. -- €	725. -- €	765. -- €	320. -- €	360.-- €	
Industry esnam member	795. -- €	895. -- €	935. -- €	520. -- €	560.-- €	
Industry regular	895. -- €	995. -- €	1035. -- €	595. -- €	635.-- €	
Student esnam member	335. -- €	385. -- €	425. -- €	150. -- €	190. -- €	
Student regular	435. -- €	485. -- €	500. -- €	210. -- €	250.-- €	

Evening Event on May 10: your contribution to the expenses 50.-- € (please mark)
Please note: A surcharge 25% will be added for registration on site

We accept scanned documents by E-mail and Fax transmissions

Send Registration to the European Foundation for Clinical Nanomedicine, Alemannengasse 12, P.O. Box, CH-4016 Basel, Switzerland, Phone + 41 61 695 93 95 Fax +41 61 695 93 90

European Conference for Clinical Nanomedicine, May 10-12, 2010
EXHIBITION AND UNIVERSITY VILLAGE REGISTRATION FORM
 First Come First Served Basis. Registration Deadline: March 30, 2010

Please note that there is a limitation of space and a maximum of 60 Universities shall be admitted. For the Foyer Exhibition the space is limited to 30 companies. Booths will be assigned on a first come-first served basis. You shall within 10 days of your registration receive a confirmation from the CLINAM Organising Office.

I herewith register as a participant within the

- Foyer Exhibition** (for Companies, Industrial Institutes, Societies, Network Groups)
- University Village** (for Universities, University-Institutes and Research Labs)

I register as: Company University

Company name/University Name

Responsible: Last Name First Name

Address.

Zip..... Town.....Country.....

Phone Fax

Email.....

Pricing for Exhibitors

- Exhibition Space per m²**, minimum space 4 m², maximum space 20 m² 280 €
 Exhibition Space: I book _____ m² (please indicate in letters)
 Setting: (x by y meter) _____
- Booth construction per m²**, minimum size 6 m², includes
 1 table, 2 chairs, power connection, booth labelling..... 105 €
- Transferable Exhibitor Conference Ticket** Exhibitors may buy
one transferable ticket. **It includes the lunches and the CLINAM-Evening Event for one person**..... 760 €



Pricing for University Village

- Village table (10-12 May) includes 1 Table, 2 chairs, 1 pinboard for poster, 580 €
 power connection, **and includes 1 transferable conference badge, lunch** (one person) and **Evening Event** (one person)

For all optionals and furnishing, please send request to the Exhibition Organisers' Office Congress Plus, Rosemarie Marty, contact@congress-plus.ch

Place, Date legally binding Signature

Company Stamp / University Stamp

Please send by E-mail, Mail or Fax to the organisers' office (clinam@clinam.org) or +41 61 695 93 90)

CLINAM

The reasons to attend the 3rd European Conference for Clinical Nanomedicine from May 10 – 12 in Basel, Switzerland

- Meet at the established interdisciplinary event on clinical nanomedicine in Europe.
- Attend the clinical meeting to further with your knowledge the acceleration of the development of Nanomedicine.
- Use the largest Platform in Europe for clinical debate between researchers, scientists, engineers, clinicians and experts from medicine, physics, chemistry, pharmacy, biology, biochemistry and materials science.
- Discuss the promise and limits and implications of nanomedical tools, techniques and materials in the context of unsolved medical problems and investigate the clinical evidence of established nanodrugs.
- See some pioneer-companies in the field of Nanomedicine.
- Participate in the translation of nanomedical research into products to the benefit of the patient.
- Talk to the representatives from the universities in the “University Village” and learn about their role to translate nanomedicine from research to products.

Welcome in Basel from May 10-12, 2010 (preceded on May 9 by the Business Meetings of the European Society for Nanomedicine (esnam) and the International Society for Nanomedicine (ISNM)).

Sponsors and Supporters of the 3rd European Conference for Clinical Nanomedicine



University of Basel



Agence Consulaire
de France



Freiwillige Akademische
Gesellschaft Basel



Official Conference Hotel *****



Organiser

European Foundation for Clinical Nanomedicine, Alemannengasse 12, CH 4016 Basel,
Switzerland Phone +41 61 695 93 95 Fax + 41 61 695 93 90 Email: clinam@clinam.org
Homepage: www.clinam.org